Cystic Fibrosis Therapeutics Market - Global Industry Analysis

Cystic Fibrosis Therapeutics Market- By Route of Administration (Inhaled And Oral), By Drug Class (Mucolytic, Pancreatic Enzyme Supplements, CFTR Modulators, And Bronchodilators), And By Region - Global Industry Perspective, Comprehensive Analysis, and Forecast, 2020 – 2026

Published Date: 17-Sep-2020 Category: Pharmaceutical Report Format : PDF Pages: 110 Report Code: ZMR-2895 Status : Published

Cystic Fibrosis Therapeutics market was estimated at 5,017.39 (USD Million) in 2019 and set to record a CAGR of nearly 9.1% over 2020-2026

Description

The global Cystic Fibrosis Therapeutics market was estimated at 5,017.39 (USD Million) in 2019 and set to record a CAGR of nearly 9.1% over 2020-2026. The report offers valuation and analysis of Cystic Fibrosis Therapeutics market on a global as well as regional level. The study offers a comprehensive assessment of the industry competition, limitations, sales estimates, avenues, current & emerging trends, and industry-validated market data. The report offers historical data from 2016 to 2018 along with a forecast from 2019 to 2026 based on value (USD Million).

Introduction

Cystic fibrosis is a progressive genetic disorder & chronic condition that is caused due to mutations occurring in cystic fibrosis transmembrane conductance regulator gene and obstructs the normal epithelia functioning in which it is present. Additionally, varied mutations in the gene have different impact on cystic fibrosis transmembrane conductance (CFTR) regulator resulting in various phenotypes of the disorder. Moreover, the most common gene mutation is phenylalanine occurring in codon 508 and it is found in nearly 70% of the persons suffering from cystic fibrosis. The disorder is mainly found in respiratory & gastrointestinal tracts.  According to NCBI, cystic fibrosis affects nearly 75,000 persons globally and is considered to be lethal with large number of mutations in gene limiting lung functions. The detection of cystic fibrosis gene in 1989 and new understanding pertaining to cystic fibrosis transmembrane conductance regulator protein has resulted in creation of novel cystic fibrosis therapies aimed at influencing the protein function.  The new kind of medical treatments termed as cystic fibrosis transmembrane conductance regulator (CFTR) modulators are effectively targeting myriad kinds of mutations occurring in cystic fibrosis transmembrane conductance regulator gene that is responsible for causing cystic fibrosis. These new therapies have demonstrated positive effect on the patients suffering from cystic fibrosis and have encouraged the development of new therapies that can cure the disease. Moreover, introduction of new treatments focusing on effectively managing chronic lung infection & airway clearance has shown positive results in the patients.

Market Growth Dynamics

The breakthroughs in the stem cell research and gene therapy has paved a way for the growth of cystic fibrosis therapeutics market in the recent years. Furthermore, use of gene editing treatment will also contribute notably towards the global cystic fibrosis therapeutics market size. Prominently, the new drug class referred as CFTR (cystic fibrosis transmembrane conductance regulator) modulators has the ability to modify the defect in the CFTR protein and this will boost the market trends. For the record, CFTR modulators including Ivacaftor, Lumacaftor, and Orkambi are used for correcting defect in CTFR gene for preventing cystic fibrosis.

Moreover, introduction of anti-inflammatory therapy and mucus-alteration & airway surface liquid modulation therapy are anticipated to propel the market growth over 2020-2026. In addition to this, pulmozyme treatment aids breathing in the patients through clearance of pulmonary obstructions caused due to cystic fibrosis. Another treatment for cystic fibrosis referred as PERT that makes use of porcine-derived pancrelipase enzymes are used along with liprotamaase for treating cystic fibrosis and have exhibited favorable outcomes during clinical trials. Antimicrobial drugs are also being used for treating the disease and this will culminate in the surge in the market proceeds over the forthcoming years.

North American Market To Retain Dominant Position Over 2020-2026

The growth of the market in the sub-continent over the forecast timespan is attributed to large-scale funding of research activities carried out by reputed pharma firms in the region for launching new drugs to cure the autosomal recessive disorder. Furthermore, breakthroughs witnessed in the biotechnology domain will further contribute towards the regional market growth over the ensuing years.

Key players influencing the market growth include Novartis AG, Mylan N.V., Genentech, Inc., AbbVie Inc., Vertex Pharmaceuticals Incorporated, Johnson & Johnson, Gilead Sciences, Inc., GlaxoSmithKline Plc., Allergan plc, and Pharmaxis Ltd.

The global cystic fibrosis therapeutics market is segmented as follows:

By Drug Class

  • Pancreatic Enzyme Supplements
  • Mucolytic
  • Bronchodilators
  • CFTR modulators

By Route of Administration

  • Oral
  • Inhaled

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

  • Chapter 1. Preface
    • 1.1. Report Description and Scope
    • 1.2. Research Scope
    • 1.3. Research Methodology
      • 1.3.1. Market Research Process
      • 1.3.2. Market Research Methodology
  • Chapter 2. Executive Summary
    • 2.1. Cystic Fibrosis Therapeutics Market, 2016–2026 (USD Million)
    • 2.2. Cystic Fibrosis Therapeutics Market: Snapshot
  • Chapter 3. Global Cystic Fibrosis Therapeutics Market– Industry Analysis
    • 3.1. Cystic Fibrosis Therapeutics Market: Market Dynamics
    • 3.2. Market Drivers
      • 3.2.1. Introduction of anti-inflammatory therapy and mucus-alteration & airway surface liquid modulation therapy are anticipated to propel the market growth over 2020-2026.
      • 3.2.2. The new kind of medical treatments termed as cystic fibrosis transmembrane conductance regulator (CFTR) modulators are effectively targeting myriad kinds of mutations occurring in cystic fibrosis transmembrane conductance regulator gene that is responsible for causing cystic fibrosis. This, in turn, will further drive the market growth.
    • 3.3. Porter’s Five Forces Analysis
    • 3.4. Market Attractiveness Analysis
      • 3.4.1. Market attractiveness analysis By Route of Administration
      • 3.4.2. Market attractiveness analysis By Drug Class
  • Chapter 4. Global Cystic Fibrosis Therapeutics Market– Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global Cystic Fibrosis Therapeutics Market: company market share, 2018
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New Vehicle launches
      • 4.2.3. Agreements, partnerships, cullaborations, and joint ventures
      • 4.2.4. Research and development and Regional expansion
    • 4.3. Price trend analysis
  • Chapter 5. Global Cystic Fibrosis Therapeutics Market– Route of Administration Analysis
    • 5.1. Global Cystic Fibrosis Therapeutics Market overview: By Route of Administration
      • 5.1.1. Global Cystic Fibrosis Therapeutics Market share, By Route of Administration , 2019 and 2026
    • 5.2. Inhaled
      • 5.2.1. Global Cystic Fibrosis Therapeutics Market By Inhaled, 2016–2026 (USD Million)
    • 5.3. Oral
      • 5.3.1. Global Cystic Fibrosis Therapeutics Market By Oral, 2016–2026 (USD Million)
  • Chapter 6. Global Cystic Fibrosis Therapeutics Market– Drug Class Analysis
    • 6.1. Global Cystic Fibrosis Therapeutics Market overview: By Drug Class
      • 6.1.1. Global Cystic Fibrosis Therapeutics Market share, By Drug Class , 2019 and 2026
    • 6.2. Muculytic
      • 6.2.1. Global Cystic Fibrosis Therapeutics Market By Muculytic, 2016–2026 (USD Million)
    • 6.3. Pancreatic Enzyme Supplements
      • 6.3.1. Global Cystic Fibrosis Therapeutics Market By Pancreatic Enzyme Supplements, 2016–2026 (USD Million)
    • 6.4. CFTR Modulators
      • 6.4.1. Global Cystic Fibrosis Therapeutics Market By CFTR Modulators, 2016–2026 (USD Million)
    • 6.5. Bronchodilators
      • 6.5.1. Global Cystic Fibrosis Therapeutics Market By Bronchodilators, 2016–2026 (USD Million)
  • Chapter 7. Company Profiles
    • 7.1. Novartis AG
      • 7.1.1. Overview
      • 7.1.2. Financials
      • 7.1.3. Product Portfolio
      • 7.1.4. Business Strategy
      • 7.1.5. Recent Developments
    • 7.2. Genentech, Inc.
      • 7.2.1. Overview
      • 7.2.2. Financials
      • 7.2.3. Product Portfolio
      • 7.2.4. Business Strategy
      • 7.2.5. Recent Developments
    • 7.3. Vertex Pharmaceuticals Incorporated
      • 7.3.1. Overview
      • 7.3.2. Financials
      • 7.3.3. Product Portfolio
      • 7.3.4. Business Strategy
      • 7.3.5. Recent Developments
    • 7.4. Gilead Sciences, Inc.
      • 7.4.1. Overview
      • 7.4.2. Financials
      • 7.4.3. Product Portfolio
      • 7.4.4. Business Strategy
      • 7.4.5. Recent Developments
    • 7.5. GlaxoSmithKline Plc
      • 7.5.1. Overview
      • 7.5.2. Financials
      • 7.5.3. Product Portfolio
      • 7.5.4. Business Strategy
      • 7.5.5. Recent Development
    • 7.6. AbbVie Inc.
      • 7.6.1. Overview
      • 7.6.2. Financials
      • 7.6.3. Product Portfolio
      • 7.6.4. Business Strategy
      • 7.6.5. Recent Development
    • 7.7. Allergan plc
      • 7.7.1. Overview
      • 7.7.2. Financials
      • 7.7.3. Product Portfolio
      • 7.7.4. Business Strategy
      • 7.7.5. Recent Development
    • 7.8. Johnson & Johnson
      • 7.8.1. Overview
      • 7.8.2. Financials
      • 7.8.3. Product Portfolio
      • 7.8.4. Business Strategy
      • 7.8.5. Recent Development
    • 7.9. Mylan N.V.
      • 7.9.1. Overview
      • 7.9.2. Financials
      • 7.9.3. Product Portfolio
      • 7.9.4. Business Strategy
      • 7.9.5. Recent Development
    • 7.10. Pharmaxis Ltd
      • 7.10.1. Overview
      • 7.10.2. Financials
      • 7.10.3. Product Portfolio
      • 7.10.4. Business Strategy
      • 7.10.5. Recent Development

Table Of Figures

List of Figures

1. Market research process
2. Market research methodology
3. Global Cystic Fibrosis Therapeutics Market, 2016–2026 (USD Million)
4. Porter’s Five Forces Analysis
5. Global Cystic Fibrosis Therapeutics Market attractiveness, By Route of Administration  
6. Global Cystic Fibrosis Therapeutics Market attractiveness, By Drug Class 
7. Global Cystic Fibrosis Therapeutics Market Share by Route of Administration  ,2019 and 2026 (USD Million)
8. Global Cystic Fibrosis Therapeutics Market by Inhaled,2016–2026 (USD Million)
9. Global Cystic Fibrosis Therapeutics Market by Oral ,2016–2026 (USD Million)
10. Global Cystic Fibrosis Therapeutics Market Share By Drug Class ,2019 and 2026 (USD Million)
11. Global Cystic Fibrosis Therapeutics Market by Mucolytic,2016–2026 (USD Million)
12. Global Cystic Fibrosis Therapeutics Market, By Pancreatic Enzyme Supplements, 2016–2026 (USD Million)
13. Global Cystic Fibrosis Therapeutics Market, By CFTR Modulators, 2016–2026 (USD Million)
14. Global Cystic Fibrosis Therapeutics Market, By Bronchodilators, 2016–2026 (USD Million)
15. Global Cystic Fibrosis Therapeutics Market share, by Region, 2019 and 2026
16. North America Cystic Fibrosis Therapeutics Market, 2016–2026 (USD Million)
17. Europe Cystic Fibrosis Therapeutics Market, 2016–2026 (USD Million)
18. Asia Pacific Cystic Fibrosis Therapeutics Market, 2016–2026 (USD Million)
19. Latin America Cystic Fibrosis Therapeutics Market, 2016–2026 (USD Million)
20. The Middle East and Africa Cystic Fibrosis Therapeutics Market, 2016–2026 (USD Million)


Table Of Tables

List of Tables

1. Global Cystic Fibrosis Therapeutics Market: snapshot
2. Drivers of the Cystic Fibrosis Therapeutics Market: impact analysis
3. North America Cystic Fibrosis Therapeutics Market revenue, By Route of Administration  , 2016–2026 (USD Million)
4. North America Cystic Fibrosis Therapeutics Market revenue, By Drug Class , 2016–2026 (USD Million)
5. The U.S. Cystic Fibrosis Therapeutics Market revenue, By Route of Administration  , 2016–2026 (USD Million)
6. The U.S. Cystic Fibrosis Therapeutics Market revenue, By Drug Class , 2016–2026 (USD Million)
7. Rest of North America Cystic Fibrosis Therapeutics Market revenue, By Route of Administration  , 2016–2026 (USD Million)
8. Rest of North America Cystic Fibrosis Therapeutics Market revenue, By Drug Class , 2016–2026 (USD Million)
9. Europe Cystic Fibrosis Therapeutics Market revenue, By Route of Administration  , 2016–2026 (USD Million)
10. Europe Cystic Fibrosis Therapeutics Market revenue, By Drug Class , 2016–2026 (USD Million)
11. UK Cystic Fibrosis Therapeutics Market revenue, By Route of Administration  , 2016–2026 (USD Million)
12. UK Cystic Fibrosis Therapeutics Market revenue, By Drug Class , 2016–2026 (USD Million)
13. France Cystic Fibrosis Therapeutics Market revenue, By Route of Administration  , 2016–2026 (USD Million)
14. France Cystic Fibrosis Therapeutics Market revenue, By Drug Class , 2016–2026 (USD Million)
15. Germany Cystic Fibrosis Therapeutics Market revenue, By Route of Administration  , 2016–2026 (USD Million)
16. Germany Cystic Fibrosis Therapeutics Market revenue, By Drug Class , 2016–2026 (USD Million)
17. Rest of Europe Cystic Fibrosis Therapeutics Market revenue, By Route of Administration  , 2016–2026 (USD Million)
18. Rest of Europe Cystic Fibrosis Therapeutics Market revenue, By Drug Class , 2016–2026 (USD Million)
19. Asia Pacific Cystic Fibrosis Therapeutics Market revenue, By Route of Administration  , 2016–2026 (USD Million)
20. Asia Pacific Cystic Fibrosis Therapeutics Market revenue, By Drug Class , 2016–2026 (USD Million)
21. China Cystic Fibrosis Therapeutics Market revenue, By Route of Administration  , 2016–2026 (USD Million)
22. China Cystic Fibrosis Therapeutics Market revenue, By Drug Class , 2016–2026 (USD Million)
23. Japan Cystic Fibrosis Therapeutics Market revenue, By Route of Administration  , 2016–2026 (USD Million)
24. Japan Cystic Fibrosis Therapeutics Market revenue, By Drug Class , 2016–2026 (USD Million)
25. India Cystic Fibrosis Therapeutics Market revenue, By Route of Administration  , 2016–2026 (USD Million)
26. India Cystic Fibrosis Therapeutics Market revenue, By Drug Class , 2016–2026 (USD Million)
27. Rest of Asia Pacific Cystic Fibrosis Therapeutics Market revenue, By Route of Administration  , 2016–2026 (USD Million)
28. Rest of Asia Pacific Cystic Fibrosis Therapeutics Market revenue, By Drug Class , 2016–2026 (USD Million)
29. Latin America Cystic Fibrosis Therapeutics Market revenue, By Route of Administration  , 2016–2026 (USD Million)
30. Latin America Cystic Fibrosis Therapeutics Market revenue, By Drug Class , 2016–2026 (USD Million)
31. Brazil Cystic Fibrosis Therapeutics Market revenue, By Route of Administration  , 2016–2026 (USD Million)
32. Brazil Cystic Fibrosis Therapeutics Market revenue, By Drug Class , 2016–2026 (USD Million)
33. Rest of Latin America Cystic Fibrosis Therapeutics Market revenue, By Route of Administration  , 2016–2026 (USD Million)
34. Rest of Latin America Cystic Fibrosis Therapeutics Market revenue, By Drug Class , 2016–2026 (USD Million)
35. The Middle East and Africa Cystic Fibrosis Therapeutics Market revenue, By Route of Administration  , 2016–2026 (USD Million)
36. The Middle East and Africa Cystic Fibrosis Therapeutics Market revenue, By Drug Class , 2016–2026 (USD Million)
37. Saudi Arabia Cystic Fibrosis Therapeutics Market revenue, By Route of Administration  , 2016–2026 (USD Million)
38. Saudi Arabia Cystic Fibrosis Therapeutics Market revenue, By Drug Class , 2016–2026 (USD Million)
39. South Africa Cystic Fibrosis Therapeutics Market revenue, By Route of Administration  , 2016–2026 (USD Million)
40. South Africa Cystic Fibrosis Therapeutics Market revenue, By Drug Class , 2016–2026 (USD Million)
41. Rest of the Middle East & Africa Cystic Fibrosis Therapeutics Market revenue, By Route of Administration  , 2016–2026 (USD Million)
42. Rest of the Middle East & Africa Cystic Fibrosis Therapeutics Market revenue, By Drug Class , 2016–2026 (USD Million)


 
 

Methodology

Choose License Type

FrequentlyAsked Questions

The breakthroughs in the stem cell research and gene therapy has paved a way for the growth of cystic fibrosis therapeutics market in the recent years. Furthermore, use of gene editing treatment will also contribute notably towards the global cystic fibrosis therapeutics market size. Prominently, the new drug class referred as CFTR (cystic fibrosis transmembrane conductance regulator) modulators has the ability to modify the defect in the CFTR protein and this will boost the market trends.

According to Zion Market Research Report, The global Cystic Fibrosis Therapeutics market was estimated at 5,017.39 (USD Million) in 2019 and is slated to record a revenue worth 9,805.79 (USD Million) by 2026. The CAGR of the market is projected at nearly 9.1% during forecast period.

North America is likely to make noteworthy contributions towards overall market revenue. The growth is attributed to large-scale funding of research activities carried out by reputed pharma firms in the region for launching new drugs to cure the autosomal recessive disorder. In addition to this, breakthroughs witnessed in the biotechnology domain will further contribute towards the regional market growth over the forthcoming years.

The key players profiled in the report include Novartis AG, Mylan N.V., Genentech, Inc., AbbVie Inc., Vertex Pharmaceuticals Incorporated, Johnson & Johnson, Gilead Sciences, Inc., GlaxoSmithKline Plc., Allergan plc, and Pharmaxis Ltd. The major players are trying to introduce new clinically tested drugs in the market and are focusing on various branding & promotional activities to enhance their brand image and positioning in the market. As the market is highly fragmented, players are trying to coin new strategies to retain the current customers and maintain their market position. Apart from this, these firms are exploring new business growth opportunities in countries with untapped market potential.

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (844) 845-5245
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #

US OFFICE NO +1 (844) 845-5245
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Industry Press Release

We Accept

We have secured system to process your transaction.

  • paypal
  • amazon
  • visa
  • master card

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed